Different mechanisms are involved in the deregulation of MYC expression in cancer including gene mutation and amplification as well as upregulation by activated upstream pathways namely WNT/APC/β-catenin and receptor tyrosine kinase(RTK)/RAS/MEK/ERK pathways [1], both frequently activated in colorectal cancer (CRC). This evidence concerns the gene APC and colorectal carcinoma.